<h4>Background</h4>Developing a non-invasive model is essential for assessing liver stiffness in conditions without transient elastography, which will determine further management in chronic hepatitis B (CHB) patients.<h4>Objectives</h4>This study aims to evaluate the interleukin-13 role in liver fibrosis and develop a new predictive model that includes interleukin-13 and standard data such as age and platelet count.<h4>Methods</h4>Patients were recruited from Hasan Sadikin General Hospital's CHB registry from October 2021 to January 2022. Here, IL13 is linked to Hepatic fibrosis.